Although there was no benefit at 30 days, among patients in CS due to LV dysfunction associated with an ST elevation MI, a strategy of ERV was superior to IMS at 6 and 12 months of follow-up. Patients younger than 75 years of age benefited most, with 20 lives saved at 6 months per 100 patients treated. According to the results of the SHOCK trial, ERV is now a class I indication for this patient population in the ACC/AHA myocardical infarction guidelines. Mortality with CABG was similar to that with percutaneous intervention in this high-risk population.
CHF. 2003;9(1) © 2003 Le Jacq Communications, Inc.
Cite this: Cardiogenic Shock: A Summary of the Randomized SHOCK Trial - Medscape - Jan 01, 2003.